Found this one earlier tonight...published about 3 weeks ago...good we are hitting a few different news feeds...
Link to article:
https://finfeed.com/opinion/market-wrap/rats-rant-whats-hot-whats-not-and-canberra-raiders/
Article:Paradigm Biopharmaceuticals Limited (ASX
AR)
Paradigm closed up 14% to finish at $2.88c on $7.3 million stock traded. The reason for the rise was a ground-breaking discovery, which was peer reviewed and published in the international scientific journal PLoS One, identifying the source of the pain mediator, Nerve Growth Factor (NGF) in bone cells (osteocytes) in Knee Osteoarthritis (OA) patients and that PPS (Zilosul®) inhibits NGF production in these cells and thereby reduces pain in patients with OA.
I won't bore you with any more technical biotech chat, but I did write about them in the the What's Doing section a few years ago when they were sub 50c and if you were onto that lunch is on you.
A big well done to Paul and his team at PAR and a big well done to Bell's who recently helped them raise some more Arthus Ash @ $1.50. Also, well done to any of you that has stock.
Mr. Paul Rennie, Paradigm’s Chief Executive Officer said:
“We consider peer review as the gold standard for scientific communication. We are impressed that our study was the first to identify osteocytes as the key cells within the subchondral bone that are responsible for the production of the insidious pain in knee OA patients. Most importantly, the scientific validation that PPS inhibits NGF as a mediator of bone pain in OA is a ground-breaking discovery for Paradigm."I believe that this publication should alert the interest of ‘big pharma’ who are actively trying to deal with the opiate crisis by developing pharmaceutical agents that are non-opioid, non- addictive, safe and efficacious. Paradigm continues to demonstrate that PPS meets many of the needs being sought after in treating this disease. We are showing that PPS as the active agent within our product Zilosul® is a pharmaceutical agent that curbs the disease process involved in OA at every level. That being; inflammation, cartilage protection and pain.
"Having a Mechanism of Action (MoA) which has passed the rigour of peer review is important for Paradigm’s future submissions to the Regulatory Authorities. The MoA and the patent applications also further protect Paradigms intellectual property for use of PPS in treating OA. We continue on the pathway to commercialise Zilosul® and believe this ground-breaking discovery will further attract commercial interest in Paradigm’s clinical development.”
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-243
-
- There are more pages in this discussion • 4,169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
24.5¢ | 25.0¢ | 24.5¢ | $6.096K | 24.56K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 46325 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 435 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 46325 | 0.240 |
3 | 22000 | 0.235 |
8 | 314156 | 0.230 |
6 | 135884 | 0.225 |
14 | 182054 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 435 | 1 |
0.250 | 19297 | 4 |
0.255 | 89464 | 6 |
0.260 | 6349 | 2 |
0.265 | 30000 | 1 |
Last trade - 10.24am 30/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |